You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GD2-positive sarcoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Relapsed Neuroblastoma
  • +6 more
  • C7R-GD2.CART cells
  • +2 more
  • Houston, Texas
  • +1 more
Nov 12, 2021

Osteosarcoma, Neuroblastoma Trial in Houston (genetic, biological, drug)

Active, not recruiting
  • Osteosarcoma
  • Neuroblastoma
  • GD2 T cells
  • +3 more
  • Houston, Texas
  • +1 more
Apr 16, 2021

Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

Completed
  • Sarcoma
  • +3 more
  • Anti-GD2-CAR engineered T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

SCLC, Malignant Melanoma, Sarcoma Trial (GD2-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • SCLC
  • +2 more
  • GD2-SADA:177Lu-DOTA Complex
  • (no location specified)
May 4, 2022

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Tumors Trial in Worldwide (Letetresgene autoleucel)

Active, not recruiting
  • Neoplasms
  • Letetresgene autoleucel
  • Pittsburgh, Pennsylvania
  • +5 more
Aug 7, 2023

Sarcoma Trial in Houston (Autologous HER2-specific T cells, Fludarabine, Cyclophosphamide)

Active, not recruiting
  • Sarcoma
  • Autologous HER2-specific T cells
  • +3 more
  • Houston, Texas
  • +1 more
Nov 21, 2022

Tumors Trial in Worldwide (GSK3901961, Cyclophosphamide, Fludarabine)

Terminated
  • Neoplasms
  • New Haven, Connecticut
  • +20 more
Sep 15, 2023

Kaposi's Sarcoma, HIV Positive, AIDS Trial in New Orleans (aldoxorubicin)

Completed
  • Kaposi's Sarcoma
  • +2 more
  • New Orleans, Louisiana
    Louisiana State University Health Science Center
Jan 27, 2022

Tumors Trial in Worldwide (GSK3845097, Cyclophosphamide, Fludarabine)

Terminated
  • Neoplasms
  • New Haven, Connecticut
  • +20 more
Jul 5, 2023

Non-invasive Respiratory Support on Outcome and Its Risks in

Active, not recruiting
  • COVID-19
  • Hypoxemic Respiratory Failure
  • High flow nasal oxygen (HFNO, more than 15 L/min)
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Sep 4, 2023

HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma Trial in Houston

Active, not recruiting
  • HLA-A*0201 Positive Cells Present
  • +3 more
  • Aldesleukin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Maastricht, Limburg, Netherlands
  • +4 more
Nov 7, 2022

Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma Trial in United States (Afamitresgene

Not yet recruiting
  • Synovial Sarcoma
  • +3 more
  • Afamitresgene autoleucel
  • Palo Alto, California
  • +3 more
Dec 6, 2022

Neuroblastoma Trial in New York (Humanized 3F8 Monoclonal Antibody (Hu3F8))

Active, not recruiting
  • Neuroblastoma
  • Humanized 3F8 Monoclonal Antibody (Hu3F8)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 24, 2021

Neuroblastoma Trial in New York (3F8 Monoclonal Antibody Combined with Interleukin-2)

Completed
  • Neuroblastoma
  • 3F8 Monoclonal Antibody Combined with Interleukin-2
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 26, 2021

Ewing Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma Trial in United States (PRT2527)

Recruiting
  • Ewing Sarcoma
  • +7 more
  • Denver, Colorado
  • +5 more
Jun 9, 2022

Melanoma, Melanoma, Uveal, Head Neck Cancer Trial in Rotterdam (Adoptive therapy with autologous MC2 TCR T cells)

Recruiting
  • Melanoma
  • +2 more
  • Adoptive therapy with autologous MC2 TCR T cells
  • Rotterdam, Netherlands
    Erasmus Medical Center
Jun 1, 2022

Advanced Solid Tumors Trial in United States (Drug:LM-102)

Terminated
  • Advanced Solid Tumors
  • California City, California
  • +5 more
Oct 24, 2022

Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T

Active, not recruiting
  • Urinary Bladder Cancer
  • +9 more
  • Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
  • Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
  • Miami, Florida
  • +10 more
Aug 9, 2022

Leiomyosarcoma Trial in Bad Saarow, Berlin (Dinutuximab Beta, Zoledronic acid, Interleukin-2)

Recruiting
  • Leiomyosarcoma
  • Dinutuximab Beta, Zoledronic acid, Interleukin-2
  • Bad Saarow, Germany
  • +1 more
Jun 2, 2022

Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Tumor Trial in Worldwide (G1T48, Palbociclib)

Completed
  • Carcinoma, Ductal, Breast
  • +6 more
  • Beverly Hills, California
  • +14 more
Dec 14, 2022

Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)

Active, not recruiting
  • Brain and Central Nervous System Tumors
  • +9 more
  • DNA analysis
  • +4 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 28, 2021

GD2 Positive Glioma, CAR-T Cell Immunotherapy Trial in Guangzhou (CAR-T cell immunotherapy)

Withdrawn
  • GD2 Positive Glioma
  • CAR-T Cell Immunotherapy
  • CAR-T cell immunotherapy
  • Guangzhou, Guangdong, China
    Central laboratory in Fuda cancer hospital
Jul 14, 2020